VERTEX PHARMACEUTICALS INC / MA Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price
VERTEX PHARMACEUTICALS INC / MA (VRTX) had Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price of $170.54 per share as of 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Payment Arrangement, Option, Exercise Price Range, Beginning of Period
us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 · last filed 2026-02-13
- 2025-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price $170.54.
- 2024-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price $156.36.
- 2023-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price $151.37.
- 2022-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price $146.11.
| Period end | Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price |
|---|---|
| 2025-12-31 | $170.54 10-K · filed 2026-02-13 |
| 2024-12-31 | $156.36 10-K · filed 2025-02-13 |
| 2023-12-31 | $151.37 10-K · filed 2024-02-15 |
| 2022-12-31 | $146.11 10-K · filed 2023-02-10 |
| 2021-12-31 | $141.76 10-K · filed 2022-02-09 |
| 2020-12-31 | $140.47 10-K · filed 2021-02-11 |
| 2020-09-30 | $140.26 10-Q · filed 2020-10-30 |
| 2020-06-30 | $139.99 10-Q · filed 2020-07-31 |
| 2020-03-31 | $137.34 10-Q · filed 2020-05-01 |
| 2019-12-31 | $134.92 10-K · filed 2020-02-13 |
| 2019-09-30 | $128.89 10-Q · filed 2019-10-31 |
| 2019-06-30 | $126.39 10-Q · filed 2019-08-01 |
| 2019-03-31 | $124.11 10-Q · filed 2019-05-01 |
| 2018-12-31 | $111.46 10-K · filed 2019-02-13 |
| 2018-09-30 | $111.22 10-Q · filed 2018-10-25 |
| 2018-06-30 | $103.58 10-Q · filed 2018-07-26 |
| 2018-03-31 | $103.03 10-Q · filed 2018-04-27 |
| 2017-12-31 | $91.57 10-K · filed 2018-02-15 |
| 2017-09-30 | $91.28 10-Q · filed 2017-10-30 |
| 2017-06-30 | $86.12 10-Q · filed 2017-07-28 |
| 2017-03-31 | $82.60 10-Q · filed 2017-04-28 |
| 2016-12-31 | $81.41 10-K · filed 2017-02-23 |
| 2016-09-30 | $80.99 10-Q · filed 2016-10-31 |
| 2016-06-30 | $79.37 10-Q · filed 2016-08-01 |
| 2016-03-31 | $78.61 10-Q · filed 2016-05-03 |
| 2015-12-31 | $75.99 10-K · filed 2016-02-16 |
| 2015-09-30 | $74.90 10-Q · filed 2015-10-30 |
| 2015-06-30 | $66.92 10-Q · filed 2015-08-04 |
| 2015-03-31 | $65.17 10-Q · filed 2015-05-04 |
| 2014-12-31 | $56.81 10-K · filed 2015-02-13 |
| 2014-09-30 | $56.20 10-Q · filed 2014-11-06 |
| 2014-06-30 | $49.77 10-Q · filed 2014-07-31 |
| 2014-03-31 | $48.89 10-Q · filed 2014-05-05 |
| 2013-12-31 | $44.40 10-K · filed 2014-02-11 |
| 2013-09-30 | $44.47 10-Q · filed 2013-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |